Table 2.
Descriptive statistics for side effects, medications, and beliefs about medicines at baseline and 6-month follow-up
| Variables | Patient numbers | |
|---|---|---|
| Baseline (n = 100) | Follow-up (n = 87) | |
| Side Effects Scale (M, SD, Cronbach’s alpha) | 4.31 ± 2.31, α=.81 | 2.24 ± 1.81, α=.84 |
| Bothered by side effects from arthritis medication (1-5), (M, SD) | 2.72 ± 1.33 | 1.68 ± 0.98 |
| Self-changed prescribed medication due to side effects | 51 (51 %) | 17 (19.5 %) |
| Taken non-prescribed medication to relieve side effects | 38 (38 %) | 15 (17.2 %) |
| Reported any side effects to your doctor | 70 (70 %) | 21 (27.7 %) |
| Incidence of side effects § | 77 (77%) | 45 (51.7%) |
| Type of side effects in free format # | ||
| Abdominal discomfort (stomach pain, cramps, etc.) | 27 (27 %) | 15 (17.2 %) |
| Skin reactions (rash, ulcer, sores, allergies) | 18 (18 %) | 7 (8.0 %) |
| Nausea | 15 (15 %) | 8 (9.2 %) |
| Weight loss/gain | 12 (12 %) | 3 (3.4 %) |
| Fatigue | 10 (10 %) | 5 (5.7 %) |
| Diarrhea, vomiting | 7 (7 %) | 1 (1.1 %) |
| Headache | 5 (5 %) | 5 (5.7 %) |
| Medication regimen | ||
| Symptomatic drugs | 73 (73 %) | 60 (68.9 %) |
| Steroids | 30 (30 %) | 25 (28.7 %) |
| DMARDs | 58 (58 %) | 45 (51.7 %) |
| Biologic response modifiers | 48 (48 %) | 44 (50.6 %) |
| New drug prescription within 6-months follow-up | - | 17 (19.5 %) |
| BMQ subscales (M, SD, Cronbach’s alpha) | ||
| General Harm (1-20) | 8.86 ± 2.83, α=.68 | 8.57 ± 2.47, α=.61 |
| General Overuse (1-20) | 11.56 ± 3.09, α=.74 | 11.21 ± 2.78, α=.69 |
| Specific Necessity (1-25) | 19.63 ± 3.77, α=.82 | 19.62 ± 3.72, α=.81 |
| Specific Concern (1-30) | 17.01 ± 4.29, α=.73 | 16.63 ± 3.73, α=.71 |
Note. M = Mean; SD = standard deviation
Incidence was defined as the proportion of patients who were at least mildly bothered by side effects or agreed to any of the other three side effect questions
Reported are side effects with a base rate > 5%; DMARDs = Disease modifying anti-rheumatic drugs; BMQ = Beliefs about Medicines Questionnaire.